MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock upon...
$183,235K
Proceeds from issuance of
pre-funded warrants
$141,000K
Proceeds from issuance of
common stock related to...
$33,202K
(32.89%↑ Y/Y)
Proceeds from espp
purchase
$922K
(12.44%↑ Y/Y)
Proceeds from exercise of
common stock options
$851K
(-44.88%↓ Y/Y)
Net cash provided by
financing activities
$359,210K
(1213.48%↑ Y/Y)
Net increase in
cash, cash...
$115,067K
(280.17%↑ Y/Y)
Canceled cashflow
$244,143K
Maturities of marketable
securities
$158,367K
(-56.07%↓ Y/Y)
Stock-based compensation
$16,658K
(-24.64%↓ Y/Y)
Accounts payable
$8,890K
(276.06%↑ Y/Y)
Accrued and other
liabilities
$7,793K
(0.97%↑ Y/Y)
Lease liabilities
$707K
(-42.98%↓ Y/Y)
Depreciation and
amortization
$688K
(-47.80%↓ Y/Y)
Amortization of right-of-use
assets
$433K
(-58.68%↓ Y/Y)
Net cash (used in)
provided by investing...
-$155,932K
(-224.02%↓ Y/Y)
Net cash used in
operating activities
-$88,211K
(28.18%↑ Y/Y)
Canceled cashflow
$158,367K
Canceled cashflow
$35,169K
Purchases of marketable
securities
$313,433K
(34.66%↑ Y/Y)
Net loss
-$112,452K
(24.87%↑ Y/Y)
Purchases of property and
equipment, net
$866K
(-56.55%↓ Y/Y)
Contract assets
$9,445K
Prepaid expenses and
other assets
$1,052K
(-57.41%↓ Y/Y)
Net accretion of
discounts on marketable...
$1,018K
(-84.27%↓ Y/Y)
Back
Back
Cash Flow
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)
source: myfinsight.com